Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director · President & CEO | March 01, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 212,327 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Tax withholding · Disposed 8,954 · Balance 212,327 F1: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. F2: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.
F2: Includes shares of common stock underlying unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 4, 2022 00:12 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon stock, $0.0001 par value | 8,954 | $0.82 | $7,351.23 |
DisclosureSEC source: 0001209191-22-015893 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,327 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:03 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 126,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010384 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,281 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in three equal annual installments. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 13:11 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 6,000 | $1.63 | $9,780.00 |
DisclosureSEC source: 0001209191-21-051759 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,281 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 12:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 1,953 | $2.56 | $4,999.68 |
DisclosureSEC source: 0001209191-21-018054 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,281 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 02:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,500 | $3.03 | $7,575.00 |
DisclosureSEC source: 0001209191-21-017569 · doc4.xml · nonDerivative · entry 2 Dispersyn Gerrit · CIK 0001704417 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,328 F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 02:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 68,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017569 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,828 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in three equal annual installments. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 19, 2020 Filed Aug 19, 2020 21:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,000 | $2.50 | $5,000.00 |
DisclosureSEC source: 0001209191-20-047533 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,377 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:27 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon stock, $0.0001 par value | 673 | $2.93 | $1,971.89 |
DisclosureSEC source: 0001209191-20-015801 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,628 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 15, 2020, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-55. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:35 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 350,000 | $0.10 | $35,000.00 |
DisclosureSEC source: 0001209191-19-057511 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,817 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 01, 2019 Filed Aug 3, 2019 00:36 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon stock, $0.0001 par value | 1,236 | $0.40 | $498.11 |
DisclosureSEC source: 0001209191-19-044367 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,817 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock | 407,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017201 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,053 F1 · shares: As reported on the Current Report on Form 8-K filed on February 15, 2019 and pursuant to the reporting person's appointment as CEO, the securities reported represent shares underlying a restricted stock unit, of which shares will vest in four equal annual installments. Additionally, the reporting person's right to receive the underlying shares at vesting is subject to stockholder approval of an increase in the authorized shares under the Company's equity compensation plan. In the event that such an increase is not approved, then no shares will be issued at the applicable vesting date. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010820 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,350 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| August 01, 2018 Filed Aug 4, 2018 01:28 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-045455 · doc4.xml · derivative · entry 2 Dispersyn Gerrit · CIK 0001704417 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common stock · 16,000 shares Expires 2028-08-01 F2 · derivative.exercise_date: The stock option will vest in four equal annual installments. Read SEC document |
| August 01, 2018 Filed Aug 4, 2018 01:28 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045455 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,350 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 12:23 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 3,500 | $0.62 | $2,170.00 |
DisclosureSEC source: 0001209191-17-041790 · doc4.xml · nonDerivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 22:36 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001209191-17-028260 · doc4.xml · derivative · entry 1 Dispersyn Gerrit · CIK 0001704417 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common stock · 95,000 shares Expires 2027-04-24 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over four years beginning on the first monthly anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.